Investor Announcements - 2015
|
| ||
EKF Diagnostics, announces that it has introduced a new diabetic biomarker test that provides a 2-3 week indicator of average blood glucose. | ||
| ||
EKF announces the appointment of Panmure Gordon (UK) Limited as its Nominated Adviser and Broker. | ||
| ||
EKF Diagnostics Holdings plc provides the following trading update for the year ended 31 December 2014. | ||
| ||
EKF Diagnostics announces that it has agreed a collaboration with specialist medtech company ANGLE plc (AIM: AGL), to investigate the combination of ANGLE’s Parsortix circulating tumour cell (CTC) harvesting platform with EKF’s PointMan™ DNA enrichment technology as a liquid biopsy. | ||
| ||
Collaboration with specialist medtech company ANGLE to investigate CTC harvesting platform. | ||
| ||
EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm point of care (POC) hemoglobin analyzer at Arab Health 2015, 26-29th January, Dubai, UAE. Also on Stand Z1G30, EKF will be discussing its new liquid-stable assay* for early sepsis detection, as well as previewing SensPoint, a new hand-held lactate analyzer with built-in connectivity functions to hospital or laboratory information systems. | ||
| ||
| ||
Cash payment of £1.425m as a settlement for the total deferred cash consideration due in relation to DiaSpect Medical AB. | ||
| ||||||||||
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.